Full-Time
Validation Technician
Posted on 9/3/2025
Azenta
1,001-5,000 employees
Automated cold-chain sample management and multiomics
No salary listed
Indianapolis, IN, USA
In Person
 Mechanical Engineering (1) |
|---|
- High school diploma or GED
- Experienced with Microsoft Word, Excel and SharePoint required
- Must be mechanically inclined (works well with tools/machinery, adept at fixing or putting things together)
- Ability to learn and use facility management software platforms
- Ability to learn and use basic project management skills
- Strong communication skills (written and oral)
- Ability to manage, prioritize and deliver on core responsibilities in a fast paced and dynamic environment
- Monitor and validate freezer storage environments
- Enter data into CMMS system
- Completes all necessary documentation in an appropriate and quality driven manner
- Receive, unbox, install, setup and validate new freezers
- Perform weekly maintenance tasks on freezers and LN2 tanks
- Perform monthly, quarterly and annual maintenance tasks on freezers and LN2 tanks
- Respond to requests for information in a timely manner
- Pro-actively communicates all issues to appropriate personnel
- Operates industrial equipment as needed (Fork truck, Scissor lift, floor scrubber etc.)
- Maintains high level and consistent communication with Facilities Manager
- Complete basic building maintenance and general repair activities
- Occasional general cleaning duties required
- May become involved in special projects
- 1-2 years previous experience with validation equipment and processes preferred
- Experience in a regulated industry preferred
- Experience with equipment maintenance and lifecycle preferred
Azenta provides end-to-end life sciences solutions focused on sample management and genomic services. Its SMS segment offers automated ultra-cold storage, cryogenics, consumables, instruments, and repository services, while the Multiomics segment (GENEWIZ) provides genomic services like sequencing and gene synthesis. The company integrates hardware, consumables, software, and biorepository capabilities to collect, store, and analyze samples across pharma, biotech, academia, and healthcare, with about 55% recurring revenue. Its goal is to speed up drug development, clinical research, and advanced cell therapies by maintaining sample integrity from collection to data analysis.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Burlington, Massachusetts
Founded
1978
Simplify's Take
What believers are saying
- Trey Martin's April 2026 appointment scales Multiomics gene synthesis globally.
- UK Biocentre March 2026 acquisition expands European biorepository capabilities.
- $565 million cash enables investments post-B Medical divestiture.
What critics are saying
- $149 million May 2026 goodwill impairment triggers securities fraud probes.
- Multiomics $112.4 million charge from gene synthesis competition delays profits.
- North American demand drop slashes FY26 revenue guidance to -2% to +1%.
What makes Azenta unique
- Azenta provides automated cryogenic storage like CryoArc Pico for -190°C biobanking.
- FluidX acoustic tubes enable direct nanolitre transfers in drug discovery workflows.
- GENEWIZ multiomics delivers next-generation sequencing and gene synthesis services.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Company News
Azenta Life Sciences has appointed Trey Martin as President of its Multiomics business, effective 6 April 2026. Martin will lead the division's strategy focused on scaling global synthesis capabilities, strengthening operations and driving profitable growth across the integrated Multiomics platform. Martin brings over 30 years of life sciences experience, most recently serving as CEO of Maravai Life Sciences. He previously held senior roles at Danaher Corporation, including President of Integrated DNA Technologies, where he spent more than two decades driving global expansion and sustained double-digit growth. Ginger Zhou is stepping down from the Multiomics President role and will serve in an advisory capacity through November 2026 to ensure continuity. The appointment aims to accelerate execution of Azenta's Multiomics long-range plan outlined at its December 2025 Investor Day.
Unique tube technology enhances sample management workflows. Azenta Life Sciences reports how its unique Acoustic tube technology is enabling fully acoustic workflows promoting faster, more efficient sample management in next-generation compound management and screening workflows. Widely used in drug discovery, acoustic liquid handling uses focused ultrasonic energy to transfer liquids without physical contact, delivering highly precise dispensing in the nanolitre range. By removing pipette tips, the technology also reduces cross-contamination risk and variability, However, many workflows remain constrained by plate-based storage and intermediate reformatting steps, limiting the full efficiency and scalability of acoustic systems. Acoustic tube technology from Azenta Life Sciences addresses this challenge by enabling direct acoustic transfer from storage to assay, allowing the sample tube itself to function as the acoustic source. This removes the need for intermediate plates and eliminates tip-based handling, enabling fully acoustic, end-to-end workflows from sample storage through to assay-ready plate generation. This pioneering technology combines the proven benefits of FluidX(TM) 2D-coded sample tubes with compatibility for advanced acoustic liquid handling systems, including the Echo Liquid Handlers from Beckman Coulter Life Sciences. This integration simplifies compound management workflows while improving speed, reproducibility and data quality. In addition, acoustic tube-based workflows enable significant reductions in compound usage through low working volumes, minimal dead volume requirements and nanolitre-scale dispensing. Typical tube volumes are on the order of tens of microlitres, allowing compounds to be used more efficiently and extending library lifetime. Direct, single-sample access also reduces unnecessary sample exposure, minimising freeze-thaw cycles and preserving compound integrity over time. This format also improves cherry-picking efficiency by enabling rapid access to individual compounds without the need to retrieve and process multiple plates, reducing handling steps and simplifying workflows. Designed specifically for acoustic applications, FluidX(TM) acoustic tubes are optimised for efficient transmission of acoustic energy, ensuring consistent droplet ejection without compromising accuracy or precision. Their compact format reduces storage footprint while maintaining compatibility with automated systems. Each tube incorporates a unique 2D4 quad code on the base, enabling robust sample tracking and traceability without interfering with acoustic transfer. Engineered for long-term storage and repeated automated handling, acoustic tubes support high levels of sample integrity, auditability and automation compatibility. As drug discovery continues to evolve toward higher throughput and increased efficiency, acoustic tube-based workflows provide a scalable foundation for next-generation sample management. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information on Acoustix tubes please visit www.azenta.com Azenta, Inc. is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Its global team delivers and supports these products and services through its industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta Life Sciences announces leadership transition to accelerate gene synthesis strategy and multiomics execution. BURLINGTON, Mass., April 7, 2026 /PRNewswire/ - Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer. This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market adoption and performance. Ginger Zhou will step down from her role as President of the Multiomics business and will continue to support the Company in an advisory capacity through November 2026 to ensure continuity and a smooth transition as the business advances into its next phase of execution. "Trey is exceptionally well positioned to lead the next phase of our Multiomics strategy," said John Marotta, President and CEO. "He brings more than 30 years of leadership experience across life sciences operations, with deep expertise in scaling global synthesis and genomics platforms and a proven track record of building and operating complex, high-growth businesses. We are confident Trey is the right leader to accelerate our long-range plan and further strengthen the Multiomics platform. I would also like to thank Ginger for her leadership and for helping establish a strong foundation for the Multiomics business as we enter this next phase." Mr. Martin most recently served as Chief Executive Officer and a member of the Board of Directors of Maravai Life Sciences, where he led strategic and operational transformation across a multi-segment life sciences platform. Prior to Maravai, he served in senior leadership roles at Danaher Corporation, including Senior Vice President, Genomic Medicines, and President of Integrated DNA Technologies (IDT). Mr. Martin joined Danaher following their 2018 acquisition of IDT, after helping to lead the sale process. Prior to acquisition, Mr. Martin spent more than two decades at IDT in positions of increasing responsibility where he helped drive global expansion through organic and inorganic growth investments, sustaining double-digit growth for the entire period. Mr. Martin holds a bachelor's degree in biochemistry from the University of Iowa. "I am excited to join Azenta and lead the Multiomics team," said Trey Martin. "The business has a strong foundation with deep global expertise and an important role enabling scientists from foundational research to the clinic. I see tremendous opportunities to further differentiate and scale Azenta's unique genomics services and synthesis capabilities to meet the evolving needs of our global customers. I am eager to hit the ground running to execute our strategic priorities, drive operational excellence, and deliver sustainable, profitable growth." About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Its global team delivers and supports these products and services through its industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expectations related to its Multiomics strategy, execution priorities, and future updates following a leadership transition. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, those described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. INVESTOR CONTACT for Azenta Life Sciences: Yvonne Perron Vice President, Financial Planning & Analysis and Investor Relations [email protected] Maria Isabel Cuartas Manager, Investor Relations [email protected] SOURCE Azenta
Company profile for Azenta, Inc. (AZTA) stock, with a description, list of executives, contact details and other key facts.
Azenta is executing a turnaround under CEO John Marotta, who joined in September 2024, focusing on portfolio simplification, operational improvements and resource reallocation. The company has divested B Medical, cut approximately 340 corporate and 40 SMS roles, and shifted spending from general administration into research and sales. Operational projects under the "ABS" Kaizen methodology have delivered early results: GENEWIZ delivery times dropped from 25 days to nine hours, sample registration backlogs fell from weeks to days, and on-time delivery improved from 15% to 65%, targeting 95%. The company generates approximately $600 million in revenue with 55% recurring, serves 14,000 customers across pharmaceutical, biotech and academic sectors, and holds $550 million in cash for margin improvements, growth investments, acquisitions and buybacks. Azenta estimates its serviceable market at $6 billion with current 10% penetration.